Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;47(2):203-11.
doi: 10.1038/bmt.2011.69. Epub 2011 Mar 28.

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

S M Luger  1 , O Ringdén, M-J Zhang, W S Pérez, M R Bishop, M Bornhauser, C N Bredeson, M S Cairo, E A Copelan, R P Gale, S A Giralt, Z Gulbas, V Gupta, G A Hale, H M Lazarus, V A Lewis, M C Lill, P L McCarthy, D J Weisdorf, M A Pulsipher
Affiliations

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

S M Luger et al. Bone Marrow Transplant. 2012 Feb.

Abstract

Although reduced-intensity conditioning (RIC) and non-myeloablative (NMA)-conditioning regimens have been used for over a decade, their relative efficacy vs myeloablative (MA) approaches to allogeneic hematopoietic cell transplantation in patients with AML and myelodysplasia (MDS) is unknown. We compared disease status, donor, graft and recipient characteristics with outcomes of 3731 MA with 1448 RIC/NMA procedures performed at 217 centers between 1997 and 2004. The 5-year univariate probabilities and multivariate relative risk outcomes of relapse, TRM, disease-free survival (DFS) and OS are reported. Adjusted OS at 5 years was 34, 33 and 26% for MA, RIC and NMA transplants, respectively. NMA conditioning resulted in inferior DFS and OS, but there was no difference in DFS and OS between RIC and MA regimens. Late TRM negates early decreases in toxicity with RIC and NMA regimens. Our data suggest that higher regimen intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles for both regimen intensity and graft vs leukemia in these diseases. Prospective studies comparing regimens are needed to confirm this finding and determine the optimal approach to patients who are eligible for either MA or RIC/NMA conditioning.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: None

Figures

Figure 1
Figure 1
Cumulative incidence of (a) acute and (b) chronic GVHD after peripheral blood stem cell or bone marrow allogeneic transplant for AML or MDS, by conditioning regimen.
Figure 1
Figure 1
Cumulative incidence of (a) acute and (b) chronic GVHD after peripheral blood stem cell or bone marrow allogeneic transplant for AML or MDS, by conditioning regimen.
Figure 2
Figure 2
Cumulative incidence of (a) treatment-related mortality and (b) relapse after peripheral blood stem cell or bone marrow allogeneic transplant for AML or MDS, by conditioning regimen.
Figure 2
Figure 2
Cumulative incidence of (a) treatment-related mortality and (b) relapse after peripheral blood stem cell or bone marrow allogeneic transplant for AML or MDS, by conditioning regimen.
Figure 3
Figure 3
Adjusted probability of (a) disease-free and (b) overall survival after peripheral blood stem cell or bone marrow allogeneic transplant for AML or MDS, by conditioning regimen.
Figure 3
Figure 3
Adjusted probability of (a) disease-free and (b) overall survival after peripheral blood stem cell or bone marrow allogeneic transplant for AML or MDS, by conditioning regimen.
See this image and copyright information in PMC

References

    1. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, et al. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant. 2007;40(4):349–54. - PubMed
    1. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79(10):2578–82. - PubMed
    1. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110(4):1379–87. - PMC - PubMed
    1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91 (3):756–63. - PubMed
    1. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–400. - PubMed

Publication types